A brief description of this therapy here: https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=782631
First in human case study here: https://www.ncbi.nlm.nih.gov/pubmed/26279503
An interesting thing about doxorubicin is that it's a bona fide inducer of immunogenic cell death, which means it kills cells in such a way that the dying cell releases danger signals that arouse an immune response. http://journal.frontiersin.org/article/10.3389/fimmu.2015.00187/full
A brief description of this therapy here:
ReplyDeletehttps://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=782631
First in human case study here:
https://www.ncbi.nlm.nih.gov/pubmed/26279503
An interesting thing about doxorubicin is that it's a bona fide inducer of immunogenic cell death, which means it kills cells in such a way that the dying cell releases danger signals that arouse an immune response.
http://journal.frontiersin.org/article/10.3389/fimmu.2015.00187/full